A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä

Outcomes of primary graft failure in acute myeloid leukemia patients following unrelated transplantation with post-transplant cyclophosphamide: a study from the ALWP/EBMT




TekijätNagler, Arnon; Galimard, Jacques-Emmanuel; Kayser, Sarah; Kulagin, Alexander; Blaise, Didier; Parovichnikova, Elena; Versluis, Jurjen; Itälä-Remes, Maija; Choi, Goda; Martino Bufarull, Rodrigo; Sica, Simona; Roeven, Mieke W. H.; von dem Borne, Peter; Bazarbachi, Ali; Sanz, Jaime; Mohty, Mohamad; Ciceri, Fabio

KustantajaSpringer Nature

Julkaisuvuosi2025

Lehti:Bone Marrow Transplantation

ISSN0268-3369

eISSN1476-5365

DOIhttps://doi.org/10.1038/s41409-025-02726-8

Verkko-osoitehttps://doi.org/10.1038/s41409-025-02726-8

Rinnakkaistallenteen osoitehttps://research.utu.fi/converis/portal/detail/Publication/504767559


Tiivistelmä

We assessed pGF in 2497 AML patients undergoing HSCT from 8-10/10 HLA-matched UD with PTCy. pGF was defined as failure to achieve an ANC ≥ 0.5 × 109/L by day +30 after HSCT. The day +30 cumulative incidence of ANC was 92.6% (95%CI: 91.5–93.6), and the incidence of death without ANC recovery was 1.8% (95% CI: 1.3%–2.3%), corresponding to 141 (5.6%) patients not achieving an ANC ≥ 0.5 × 109/L by day +30. PB was the graft source in 89.4% of the patients, and 56% received reduced-intensity conditioning. 21 patients underwent a second HSCT (15 in the absence of ANC recovery and 6 after ANC recovery). 1-y NRM and RI post-pGF were 22.1% and 22.4%, respectively. 1-y LFS and OS post-pGF were 59% and 55.5%, respectively. ANC recovery evaluated as a time-dependent covariate, KPS ≥ 90, and being in CR at the time of HSCT were associated with improved OS. In conclusion, the incidence of pGF post-unrelated HSCT with PTCy was 5.6%. Of the patients who failed to engraft by day +30, 70.9% did so by day +60. A second transplant can save some of the patients with pGF.


Ladattava julkaisu

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.




Julkaisussa olevat rahoitustiedot
Open access funding provided by Tel Aviv University.


Last updated on 2025-13-11 at 14:39